CEMI实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (28 Apr 2023 @ 04:00):

Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases...

Stats
今日成交量	351 642
平均成交量	538 392
市值	16.71M
EPS	$-0.0352 ( Q4 \| 2023-03-29 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.632 (Sector) 42.63 (Industry) 0
ATR14	$0.0250 (5.49%)

ACRS -0.90%

AKU -17.87%

APDN -0.73%

BDSX 2.00%

BIOC 0.00%

BNGO -7.69%

BNR 1.05%

CDNA 7.92%

CEMI 0.22%

CHEK -0.99%

CNTG -3.80%

CSTL 2.88%

DMTK -11.32%

DRIO 1.71%

EXAS -5.03%

FLDM -7.02%

FLGT -2.39%

GENE 1.35%

GH -0.59%

GTH 0.12%

HTGM 0.00%

ICLR 0.08%

IDXX -1.37%

ILMN -1.95%

ISPC -1.87%

LAB 0.00%

LMDX 0.00%

MDXH 0.84%

ME -7.58%

MEDP -2.94%

MYGN 0.62%

MYNZ -14.13%

NDRA -5.73%

NEO 3.97%

NEOG -2.07%

NOTV -4.05%

NTRA -1.56%

OCDX 0.92%

OLK 0.75%

OPGN 0.39%

OPK -0.79%

PMD 2.11%

PRPO 4.85%

PSNL -3.31%

RDNT 0.03%

SERA 3.50%

SHC -0.25%

SQL 0.00%

STIM -1.10%

STRR 2.71%

STRRP 8.67%

SYNH 0.02%

TRIB 2.90%

TTOO -1.66%

TWST 3.79%

VIVO 0.00%

XGN -1.62%

Insider Trading

Date	Person	Action	Amount	type
2023-03-11	Angelico Paul	Buy	29 333	Common Stock
2023-03-15	Angelico Paul	Buy	7 885	Common Stock
2023-03-15	Angelico Paul	Sell	2 843	Common Stock
2023-03-11	Angelico Paul	Sell	10 575	Common Stock
2023-03-11	Angelico Paul	Sell	29 333	Restricted stock units

INSIDER POWER
-90.53
Last 100 transactions
Buy: 781 277 \| Sell: 10 790 554

音量相关性

長: 0.06 (neutral)

短: 0.14 (neutral)

Signal:(58.078) Neutral

Chembio Diagnostics Inc 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Chembio Diagnostics Inc 相关性 - 货币/商品

-0.22
( neutral )

-0.04
( neutral )

0.00
( neutral )

0.37
( neutral )

0.84
( strong )

0.29
( neutral )

Chembio Diagnostics Inc 财务报表

Annual	2022
营收:	$48.34M
毛利润:	$9.76M (20.19 %)
EPS:	$-0.960

FY	2022
营收:	$48.34M
毛利润:	$9.76M (20.19 %)
EPS:	$-0.960

FY	2021
营收:	$47.82M
毛利润:	$13.32M (27.86 %)
EPS:	$-1.400

FY	2020
营收:	$30.45M
毛利润:	$6.58M (21.60 %)
EPS:	$-1.340

Financial Reports:

No articles found.

Chembio Diagnostics Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Chembio Diagnostics Inc

Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for COVID-19, HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue, chikungunya, Chagas, ebola, leishmaniasis, lassa, marburg, leptospirosis, rickettsia, and Burkholderia diseases. The company sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, and DPP trademarks, as well as sells its products directly through distributors to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. It has collaboration agreements with Bill & Melinda Gates Foundation, The Paul G. Allen Family Foundation, The Oswaldo Cruz Foundation, and the Foundation for Innovative New Diagnostics, as well as U.S. government agencies, such as Centers for Disease Control and Prevention, the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services, and the U.S. Department of Agriculture. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Hauppauge, New York.